PHAR Company Profile and Key Details

Q: Who are the executives of PHAR?

Mr. Ruud Van OutersterpChief Ethics & Compliance OfficerMs. Mireille Sanders M.Sc.Chief Operations OfficerMr. Anurag RelanChief Medical OfficerSusanne EmbletonInvestor Relations Mang.Mr. Stephen ToorChief Commercial Officer & Pres of Pharming Healthcare, Inc.Mr. Jeroen WakkermanChief Financial OfficerDr. Sijmen de Vries M.B.A., M.D., MBAPres, Chief Executive Officer & Executive DirectorDr. Bruno M. L. GiannettiConsultantDr. Anurag Relan M.D., MPHChief Medical Officer

NASDAQ : PHAR

Pharming Group NV

$16.53

0.175+1.07%

At Close 4:00 PM

54.7

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pharming Group N.V. (PHAR) stock surged +2.72%, trading at $16.98 on NASDAQ, up from the previous close of $16.53. The stock opened at $16.85, fluctuating between $16.65 and $16.98 in the recent session.

Stock Snapshot

16.53

Prev. Close

1.19B

Market Cap

16.6515

Day Low

424.5

P/E Ratio

0.04

EPS (TTM)

-0.27

Cash Flow per Share

16.85

Open

70.24M

Number of Shares

16.98

Day High

950.09%

Free Float in %

3.26

Book Value

2.11K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	16.52	16.65	16.44	16.53	3.61K
Apr 29, 2026	16.46	16.57	16.36	16.36	2.38K
Apr 28, 2026	16.41	16.55	16.41	16.42	1.41K
Apr 27, 2026	16.46	17.01	16.46	16.92	12.36K
Apr 23, 2026	16.92	16.95	16.64	16.64	5.09K
Apr 22, 2026	17.12	17.12	16.81	17.08	3.54K
Apr 21, 2026	17.22	17.22	16.88	17.13	4.4K
Apr 20, 2026	17.64	17.85	17.31	17.57	10.89K
Apr 17, 2026	17.61	17.68	17.34	17.34	7.02K
Apr 16, 2026	17.49	17.67	17.05	17.33	7.69K
Apr 14, 2026	17.59	18.11	17.59	17.68	22.19K
Apr 13, 2026	17.29	17.38	16.83	16.96	37.93K
Apr 10, 2026	17.57	17.57	16.85	17.09	8.32K
Apr 09, 2026	16.91	17.53	16.91	16.98	1.39K
Apr 08, 2026	17.34	17.38	16.46	16.98	25.18K
Apr 07, 2026	16.55	16.71	16.27	16.42	11.45K
Apr 06, 2026	16.34	16.80	16.33	16.50	11.28K
Apr 02, 2026	16.94	16.94	15.74	16.62	41.58K
Apr 01, 2026	17.13	17.13	16.82	16.92	2.47K
Mar 31, 2026	16.50	16.82	16.36	16.64	18.07K

Contact Details

Leiden, 2333 CR

Netherlands

https://www.pharming.com 317 152 47400

About Company

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Pharming Group N.V. (NASDAQ:PHAR) closed at $16.98 USD, gaining $0.45 (2.72%) from the previous close of $16.53. The stock is currently mid-range between its 52-week high and low $8.60 and $21.34. With a market capitalization of about $1.19 billion, Pharming Group N.V. is classified as a small-cap and shows lower-than-market volatility (beta ~0.12). Key stats such as the average daily volume over the past year has been around 20.92 thousand shares, volume is running light vs its 52-week average. Headquartered in Leiden, None, Pharming Group N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fabrice Chouraqui, the company employs approximately 404 people and listed since December 23, 2020. Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -2.53%, SMA50 -6.45%, SMA200 15.67%). The stock’s 14-day RSI is 44.33 (neutral), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.29% below its high and over 118.21% above its low. Average 10-day trading volume of 4.73 thousand shares is below the 3-month average of 23.90 thousand, indicating normal recent market interest.

Valuation Metrics

Pharming Group N.V. trades at a P/E ratio of 388.89, slightly above the S&P 500 average, with a price-to-sales ratio of 3.09 and a price-to-book ratio of 3.96 trading at moderately above to book value. The P/FCF stands at 23.88, also above market averages.

Dividend & Fair Value

Pharming Group N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $16.76. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of $0.07. The next quarter is forecast at $0.01. Next year's EPS is expected at $793.79. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $41.00 to $37.00. The high target offers 148.03% upside. The low target suggests 123.84% downside. The mean target is $38.33. This offers 131.88% upside. Pharming Group N.V. earnings surprise history is frequent misses against expectations. The quarter that ended March 12, 2026, missed forecasts by -53.33%. The prior quarter beat by 100.0%. Over the last six quarters, Apple has recorded several small beats. These include -300.0% in October 24, 2024.

Shareholding & Insider Activity

Pharming Group N.V. has 68.51 million shares outstanding. The public float is 670.71 million shares, elevated short interest at 0.01% of float. This equals 6.65 thousand shares. The short ratio is 0.51 days.

Financial & Profitability Overview

Over the trailing twelve months, Pharming Group NV generated $245.32M in revenue, or $∞ per share. Gross margin was 89.72%, operating margin -2.20%, and net profit margin -4.30%. Returns are negative, with ROA at -2.28% and ROE at -4.82%.
On valuation metrics, Pharming Group NV trades at a P/E of 388.89, P/S of 3.09 and P/B of 3.96. The current ratio is 2.59 and quick ratio is 2.03. Operationally, the company’s inventory turnover is 0.70 and cash conversion cycle is -276.09 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.42, supported by a cash flow-to-debt ratio of 0.43.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pharming Group NV posted revenue of $245.32M, down slightly from $205.62M in the prior quarter. Gross profit was $220.10M (margin 89.72%). Operating income was - $5.39M (margin -2.2%). Net income was- $10.55M (EPS $0.00).
The company ended the quarter with $213.42M in cash and short-term investments, a total debt of $171.55M, and net debt of $109.80M. Total assets were $462.85M, with equity of $218.78M. Financials further reflected weakness, with operating cash flow of - $17.30M, free cash flow of - $18.77M, and capital expenditures of - $1.46M.

Price Forecast & Outlook

Our AI price prediction model suggests that Pharming Group N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.81%, with price expected at $16.23 by May 14, 2026, within a range of $15.72 to $16.74 3-Month Outlook: Projected rise of 17.66%, reaching $19.45 by July 29, 2026, with a range of $18.68 to $20.21. 1-Year Outlook: Projected gain of 8.23%, with price at $17.89 by April 30, 2027, within a range of $16.72 to $18.85.

Key Takeaways

Pharming Group N.V. (NASDAQ:PHAR) shares are flat 1.41% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pharming Group N.V. trading at a premium to the broader market with a P/E of 388.89. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $36.33, suggesting 119.78% upside. Our AI forecast model points to short-term weakness (-1.81% over two weeks), a medium-term rise (17.66% over three months), and a longer-term gain (8.23% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pharming Group N.V. (PHAR) stock price?

Pharming Group N.V. (NASDAQ: PHAR) stock price is $16.98 in the last trading session. During the trading session, PHAR stock reached the peak price of $16.98 while $16.65 was the lowest point it dropped to. The percentage change in PHAR stock occurred in the recent session was 2.72% while the dollar amount for the price change in PHAR stock was $0.45.

PHAR's industry and sector of operation?

The NASDAQ listed PHAR is part of Biotechnology industry that operates in the broader Healthcare sector. Pharming Group N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PHAR?

Mr. Ruud Van Outersterp
Chief Ethics & Compliance Officer
Ms. Mireille Sanders M.Sc.
Chief Operations Officer
Mr. Anurag Relan
Chief Medical Officer
Susanne Embleton
Investor Relations Mang.
Mr. Stephen Toor
Chief Commercial Officer & Pres of Pharming Healthcare, Inc.
Mr. Jeroen Wakkerman
Chief Financial Officer
Dr. Sijmen de Vries M.B.A., M.D., MBA
Pres, Chief Executive Officer & Executive Director
Dr. Bruno M. L. Giannetti
Consultant
Dr. Anurag Relan M.D., MPH
Chief Medical Officer

How PHAR did perform over past 52-week?

PHAR's closing price is 96.9% higher than its 52-week low of $8.60 where as its distance from 52-week high of $21.34 is -22.54%.

How many employees does PHAR have?

Number of PHAR employees currently stands at 404.

Link for PHAR official website?

Official Website of PHAR is: https://www.pharming.com

How do I contact PHAR?

PHAR could be contacted at phone 317 152 47400 and can also be accessed through its website. PHAR operates from Darwinweg 24, Leiden, 2333 CR, Netherlands.

How many shares of PHAR are traded daily?

PHAR stock volume for the day was 2.11K shares. The average number of PHAR shares traded daily for last 3 months was 20.92K.

What is the market cap of PHAR currently?

The market value of PHAR currently stands at $1.19B with its latest stock price at $16.98 and 70.24M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	404
Beta	0.16
Sales or Revenue	$245.32M
5Y Sales Change%	0.579%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PHAR Company Profile and Key Details

Pharming Group NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics